Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of V0114CP (levocetirizine) in Seasonal Allergic Rhinitis
2008-008734-36Phase 3Terminated
- Sponsor
- Pierre Fabre Laboratories
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levocetirizine in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Change in reflective nasal symptom score over 2-week treatment. Started Feb 2009; status: terminated.
02
Drugs
levocetirizine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2008-008734-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008734-36.